Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugateSIM0613 is optimally designed ...

Trump Media—TAE Merger: Fusion's Public Market Leap

On December 17 the Trump Media & Technology Group (TMTG) announced a $6-billion all-stock merger with fusion power company ...